Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference The new mini-textbook by Kamps & Hoffmann PDF, 110 pages

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 147 articles: HTML format Text format

Single Articles

April 2020
1. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
   Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
   Clin Cancer Res. 2020;26:1776.
   PubMed     Text format    
   
   
   March 2020
2. DERCLE L, Fronheiser M, Lu L, Du S, et al
   Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.
   Clin Cancer Res. 2020 Mar 20. pii: 1078-0432.CCR-19-2942.
   PubMed     Text format     Abstract available
   
   
   
3. CASCONE T, Sepesi B, Lin H, Kalhor N, et al
   A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer.
   Clin Cancer Res. 2020 Mar 19. pii: 1078-0432.CCR-19-4180.
   PubMed     Text format     Abstract available
   
   
   
4. HSIAO TF, Wang CL, Wu YC, Feng HP, et al
   Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer.
   Clin Cancer Res. 2020 Mar 10. pii: 1078-0432.CCR-19-3972.
   PubMed     Text format     Abstract available
   
   
   February 2020
5. AGGARWAL C, Thompson JC, Chien AL, Quinn KJ, et al
   Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer.
   Clin Cancer Res. 2020 Feb 26. pii: 1078-0432.CCR-19-3663.
   PubMed     Text format     Abstract available
   
   
   
6. DAGOGO-JACK I, Yoda S, Lennerz JK, Langenbucher A, et al
   MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
   Clin Cancer Res. 2020 Feb 21. pii: 1078-0432.CCR-19-3906.
   PubMed     Text format     Abstract available
   
   
   
7. HOPKINS AM, Kichenadasse G, Garrett-Mayer E, Karapetis CS, et al
   Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab.
   Clin Cancer Res. 2020 Feb 21. pii: 1078-0432.CCR-19-2968.
   PubMed     Text format     Abstract available
   
   
   
8. LI X, Zhang L, Jiang D, Wang Y, et al
   Routine-dose and High-dose Icotinib in Advanced Non-Small Cell Lung Cancer Patients harboring EGFR Exon 21 L858R Mutation: the Randomized, Phase II, INCREASE Trial.
   Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-3064.
   PubMed     Text format     Abstract available
   
   
   
9. IVANOVA E, Kuraguchi M, Xu M, Portell A, et al
   Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies for HER2mutant non small cell lung cancer.
   Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-19-1844.
   PubMed     Text format     Abstract available
   
   
   January 2020
10. FRICK MA, Feigenberg SJ, Jean-Baptiste SR, Aguarin LA, et al
    Circulating tumor cells are associated with recurrent disease in patients with early stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-2158.
    PubMed     Text format     Abstract available
    
    
    
11. OKURA N, Nishioka N, Yamada T, Taniguchi H, et al
    ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-2321.
    PubMed     Text format     Abstract available
    
    
    
12. ISOMOTO K, Haratani K, Hayashi H, Shimizu S, et al
    Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer.
    Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-2027.
    PubMed     Text format     Abstract available
    
    
    
13. SCHOENFELD AJ, Chan JM, Kubota D, Sato H, et al
    Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.
    Clin Cancer Res. 2020 Jan 7. pii: 1078-0432.CCR-19-3563.
    PubMed     Text format     Abstract available
    
    
    November 2019
14. TAMMINGA M, de Wit S, Van De Wauwer C, van den Bos H, et al
    Release of circulating tumor cells during surgery for non-small cell lung cancer: are they what they appear to be?
    Clin Cancer Res. 2019 Nov 26. pii: 1078-0432.CCR-19-2541.
    PubMed     Text format     Abstract available
    
    
    
15. ZHANG J, Ji Z, Caushi JX, El Asmar M, et al
    Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 21. pii: 1078-0432.CCR-19-2931.
    PubMed     Text format     Abstract available
    
    
    
16. DIZIER B, Callegaro A, Debois M, Dreno B, et al
    A T-helper 1/interferon- gene signature is prognostic in the adjuvant setting of resectable high-risk melanoma but not in non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-18-3717.
    PubMed     Text format     Abstract available
    
    
    
17. SHI R, Radulovich N, Ng C, Liu N, et al
    Organoid cultures as preclinical models of non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 6. pii: 1078-0432.CCR-19-1376.
    PubMed     Text format     Abstract available
    
    
    October 2019
18. BLAKELY CM
    A new pathway emerges to interpret lung cancer genomic alterations.
    Clin Cancer Res. 2019 Oct 14. pii: 1078-0432.CCR-19-2861.
    PubMed     Text format     Abstract available
    
    
    
19. RECONDO G, Mezquita L, Facchinetti F, Planchard D, et al
    Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer.
    Clin Cancer Res. 2019 Oct 4. pii: 1078-0432.CCR-19-1104.
    PubMed     Text format     Abstract available
    
    
    September 2019
20. JEONG Y, Hellyer JA, Stehr H, Hoang NT, et al
    Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1237.
    PubMed     Text format     Abstract available
    
    
    
21. ROTOW JK, Gui P, Wu W, Raymond VM, et al
    Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1667.
    PubMed     Text format     Abstract available
    
    
    
22. GERBER DE, Infante JR, Gordon MS, Goldberg SB, et al
    Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.
    Clin Cancer Res. 2019 Sep 20. pii: 1078-0432.CCR-18-3965.
    PubMed     Text format     Abstract available
    
    
    
23. MANSFIELD AS, Zauderer MG
    Nivo-lution in Mesothelioma.
    Clin Cancer Res. 2019;25:5438-5440.
    PubMed     Text format     Abstract available
    
    
    
24. MORGENSZTERN D, Besse B, Greillier L, Santana-Davila R, et al
    Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study.
    Clin Cancer Res. 2019 Sep 10. pii: 1078-0432.CCR-19-1133.
    PubMed     Text format     Abstract available
    
    
    August 2019
25. WANG W, Huang L, Jin JY, Pi W, et al
    A Validation Study on IDO Immune Biomarkers for Survival Prediction in Non-small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early Stage Disease.
    Clin Cancer Res. 2019 Aug 30. pii: 1078-0432.CCR-19-1202.
    PubMed     Text format     Abstract available
    
    
    
26. CHANG JC, Alex D, Bott M, Tan KS, et al
    Comprehensive next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intra-pulmonary metastases: Comparison with standard histopathologic approach.
    Clin Cancer Res. 2019 Aug 30. pii: 1078-0432.CCR-19-1700.
    PubMed     Text format     Abstract available
    
    
    
27. PAILLER E, Faugeroux V, Oulhen M, Mezquita L, et al
    Acquired Resistance Mutations to ALK-Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-1176.
    PubMed     Text format     Abstract available
    
    
    
28. CHEN K, Zhao H, Shi Y, Yang F, et al
    Perioperative dynamic changes in circulating tumor DNA in lung cancer patients (DYNAMIC).
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-1213.
    PubMed     Text format     Abstract available
    
    
    
29. LANDI L, Chiari R, Tiseo M, D'Inca F, et al
    Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.
    Clin Cancer Res. 2019 Aug 15. pii: 1078-0432.CCR-19-0994.
    PubMed     Text format     Abstract available
    
    
    
30. JONNA S, Feldman RA, Swensen J, Gatalica Z, et al
    Detection of NRG1 Gene Fusions in Solid Tumors.
    Clin Cancer Res. 2019;25:4966-4972.
    PubMed     Text format     Abstract available
    
    
    
31. GRAY JE, Saltos AN, Tanvetyanon T, Haura EB, et al
    Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer.
    Clin Cancer Res. 2019 Aug 13. pii: 1078-0432.CCR-19-1305.
    PubMed     Text format     Abstract available
    
    
    
32. ISHIZAWA K, Yamanaka M, Saiki Y, Miyauchi E, et al
    CD45+CD326+ Cells are predictive of poor prognosis in Non-Small Cell Lung Cancer patients.
    Clin Cancer Res. 2019 Aug 5. pii: 1078-0432.CCR-19-0545.
    PubMed     Text format     Abstract available
    
    
    
33. JONES MR, Williamson LM, Topham JT, Lee MKC, et al
    NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.
    Clin Cancer Res. 2019;25:4674-4681.
    PubMed     Text format     Abstract available
    
    
    
34. BENAYED R, Offin M, Mullaney K, Sukhadia P, et al
    High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
    Clin Cancer Res. 2019;25:4712-4722.
    PubMed     Text format     Abstract available
    
    
    July 2019
35. DEVARAKONDA S, Sankararaman S, Herzog B, Gold KA, et al
    Circulating Tumor DNA Profiling in Small Cell Lung Cancer Identifies Potentially Targetable Alterations.
    Clin Cancer Res. 2019 Jul 12. pii: 1078-0432.CCR-19-0879.
    PubMed     Text format     Abstract available
    
    
    June 2019
36. CHALISHAZAR MD, Wait SJ, Huang F, Ireland AS, et al
    MYC-driven small cell lung cancer is metabolically distinct and vulnerable to arginine depletion.
    Clin Cancer Res. 2019 Jun 4. pii: 1078-0432.CCR-18-4140.
    PubMed     Text format     Abstract available
    
    
    May 2019
37. SU Z, Wang Z, Ni X, Duan J, et al
    Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-3571.
    PubMed     Text format     Abstract available
    
    
    
38. HU-LIESKOVAN S, Lisberg A, Zaretsky JM, Grogan TR, et al
    Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-4275.
    PubMed     Text format     Abstract available
    
    
    
39. THATCHER N, Goldschmidt JH, Thomas M, Schenker M, et al
    Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
    Clin Cancer Res. 2019;25:3193.
    PubMed     Text format    
    
    
    
40. DAGOGO-JACK I, Awad MM, Shaw AT
    BRAF Mutation Class and Clinical Outcomes-Response.
    Clin Cancer Res. 2019;25:3189.
    PubMed     Text format    
    
    
    
41. DANKNER M, Rose AAN
    BRAF Mutation Class and Clinical Outcomes-Letter.
    Clin Cancer Res. 2019;25:3188.
    PubMed     Text format    
    
    
    
42. FANG W, Ma Y, Yin JC, Hong S, et al
    Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2019 May 13. pii: 1078-0432.CCR-19-0585.
    PubMed     Text format     Abstract available
    
    
    
43. DATAR IJ, Sanmamed MF, Wang J, Henick BS, et al
    Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.
    Clin Cancer Res. 2019 May 3. pii: 1078-0432.CCR-18-4142.
    PubMed     Text format     Abstract available
    
    
    
44. SALEM A, Little RA, Latif A, Featherstone AK, et al
    Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer.
    Clin Cancer Res. 2019 May 3. pii: 1078-0432.CCR-18-3932.
    PubMed     Text format     Abstract available
    
    
    April 2019
45. XU Y, Hosny A, Zeleznik R, Parmar C, et al
    Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging.
    Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-2495.
    PubMed     Text format     Abstract available
    
    
    
46. YU H, Wu H, Wang W, Jolly S, et al
    Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-1084.
    PubMed     Text format     Abstract available
    
    
    
47. LEIGHL NB, Page RD, Raymond VM, Daniel DB, et al
    Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2019 Apr 15. pii: 1078-0432.CCR-19-0624.
    PubMed     Text format     Abstract available
    
    
    
48. MA PC
    (Not Giving Up) The Marathon Race of MET Targeting Therapy: Are We There Yet?
    Clin Cancer Res. 2019;25:2375-2378.
    PubMed     Text format     Abstract available
    
    
    
49. VAN CUTSEM E, Karaszewska B, Kang YK, Chung HC, et al
    A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.
    Clin Cancer Res. 2019;25:2414-2423.
    PubMed     Text format     Abstract available
    
    
    
50. LUSK CM, Watza D, Dyson G, Craig DB, et al
    Profiling the mutational landscape in known driver genes and novel genes in African American non-small cell lung cancer patients.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-2439.
    PubMed     Text format     Abstract available
    
    
    
51. KOH J, Kim HY, Lee Y, Park IK, et al
    IL-23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1 (ILC1) into ILC3.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3458.
    PubMed     Text format     Abstract available
    
    
    
52. VENDRELL J, Mazieres J, Senal R, Rouquette I, et al
    Ultra-sensitive EGFR (T790M)detection as an independent prognostic marker for lung cancer patients harboring EGFR (del19)mutations and treated with first-generation TKIs.
    Clin Cancer Res. 2019 Apr 1. pii: 1078-0432.CCR-18-2683.
    PubMed     Text format     Abstract available
    
    
    March 2019
53. HEIGENER DF, Kerr KM, Laing GM, Mok TSK, et al
    Redefining treatment paradigms in first-line advanced non-small cell lung cancer.
    Clin Cancer Res. 2019 Mar 25. pii: 1078-0432.CCR-18-1894.
    PubMed     Text format     Abstract available
    
    
    
54. DOROSHOW DB, Sanmamed MF, Hastings K, Politi K, et al
    Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
    Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-1538.
    PubMed     Text format     Abstract available
    
    
    
55. PELED M, Onn A, Herbst RS
    Tumor-Infiltrating Lymphocytes-Location for Prognostic Evaluation.
    Clin Cancer Res. 2019;25:1449-1451.
    PubMed     Text format     Abstract available
    
    
    February 2019
56. ZHANG Q, Zhang Y, Chen Y, Qian J, et al
    A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases and improves cancer immunity in preclinical lung cancer models.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-2548.
    PubMed     Text format     Abstract available
    
    
    
57. TREFNY MP, Rothschild SI, Uhlenbrock F, Rieder D, et al
    A Variant of a Killer Cell Immunoglobulin-like Receptor is Associated with Resistance to PD-1 Blockade in Lung Cancer.
    Clin Cancer Res. 2019 Feb 14. pii: 1078-0432.CCR-18-3041.
    PubMed     Text format     Abstract available
    
    
    
58. KNORR DA, Ravetch JV
    Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.
    Clin Cancer Res. 2019;25:904-906.
    PubMed     Text format     Abstract available
    
    
    January 2019
59. BALTSCHUKAT S, Schacher Engstler B, Huang A, Hao HX, et al
    Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Clin Cancer Res. 2019 Jan 23. pii: 1078-0432.CCR-18-2814.
    PubMed     Text format     Abstract available
    
    
    
60. YUN J, Hong MH, Kim SY, Park CW, et al
    YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2906.
    PubMed     Text format     Abstract available
    
    
    
61. PLANCHARD D, Boyer MJ, Lee JS, Dechaphunkul A, et al
    Post-Progression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2019 Jan 18. pii: 1078-0432.CCR-18-3325.
    PubMed     Text format     Abstract available
    
    
    
62. MARTINEZ P, Peters S, Stammers T, Soria JC, et al
    Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer.
    Clin Cancer Res. 2019 Jan 14. pii: 1078-0432.CCR-18-3904.
    PubMed     Text format     Abstract available
    
    
    
63. DE GOEJE PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, et al
    Induction of peripheral effector CD8 T cell proliferation by combination of paclitaxel, carboplatin and bevacizumab in non-small cell lung cancer patients.
    Clin Cancer Res. 2019 Jan 14. pii: 1078-0432.CCR-18-2243.
    PubMed     Text format     Abstract available
    
    
    
64. THATCHER N, Goldschmidt JH, Thomas M, Schenker M, et al
    Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study.
    Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-2702.
    PubMed     Text format     Abstract available
    
    
    
65. CHEN X, Chang CW, Spoerke JM, Yoh K, et al
    Low-Pass Whole-Genome Sequencing of Circulating Cell-Free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
    Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-1593.
    PubMed     Text format     Abstract available
    
    
    December 2018
66. HEYZA J, Lei W, Watza D, Zhang H, et al
    Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer.
    Clin Cancer Res. 2018 Dec 11. pii: 1078-0432.CCR-18-3094.
    PubMed     Text format     Abstract available
    
    
    
67. AKHTAR S, Meeran SM, Katiyar N, Katiyar SK, et al
    Editor's Note: Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-small Cell Lung Cancer Xenografts by Targeting Insulin-Like Growth Factor Binding Protein-3, Tumor Cell Proliferation, and Angiogenic Factors.
    Clin Cancer Res. 2018;24:6101.
    PubMed     Text format    
    
    
    November 2018
68. LI L, Li W, Chen N, Zhao H, et al
    FLI1 exonic circular RNAs as a novel oncogenic driver to promote tumor metastasis in small cell lung cancer.
    Clin Cancer Res. 2018 Nov 14. pii: 1078-0432.CCR-18-1447.
    PubMed     Text format     Abstract available
    
    
    
69. ESAI SELVAN M, Klein RJ, Gumus ZH
    Rare, pathogenic germline variants in Fanconi Anemia genes increase risk for squamous lung cancer.
    Clin Cancer Res. 2018 Nov 13. pii: 1078-0432.CCR-18-2660.
    PubMed     Text format     Abstract available
    
    
    October 2018
70. TAO Z, McCall NS, Wiedemann N, Vuagniaux G, et al
    SMAC mimetic Debio 1143 and ablative radiation therapy synergize to enhance anti-tumor immunity against lung cancer.
    Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-17-3852.
    PubMed     Text format     Abstract available
    
    
    
71. SUZAWA K, Offin M, Lu D, Kurzatkowski C, et al
    Activation of KRAS mediates resistance to targeted therapy in MET ex on 14 mutant non-small cell lung cancer.
    Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-18-1640.
    PubMed     Text format     Abstract available
    
    
    
72. ATRAFI F, Groen HJ, Byers LA, Garralda E, et al
    A Phase 1 Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-2014.
    PubMed     Text format     Abstract available
    
    
    
73. XIE Y, Lu W, Wang S, Tang X, et al
    Validation of the 12-gene predictive signature for Adjuvant Chemotherapy Response in Lung Cancer.
    Clin Cancer Res. 2018 Oct 4. pii: 1078-0432.CCR-17-2543.
    PubMed     Text format     Abstract available
    
    
    September 2018
74. DAGOGO-JACK I, Martinez P, Yeap BY, Ambrogio C, et al
    Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-2062.
    PubMed     Text format     Abstract available
    
    
    
75. LO RUSSO G, Moro M, Sommariva M, Cancila V, et al
    Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-1390.
    PubMed     Text format     Abstract available
    
    
    
76. PETERS S, Stahel RA, Bubendorf L, Bonomi P, et al
    Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety and Biomarkers.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-1590.
    PubMed     Text format     Abstract available
    
    
    
77. CORREDOR G, Wang X, Zhou Y, Lu C, et al
    Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-2013.
    PubMed     Text format     Abstract available
    
    
    August 2018
78. RICHARD C, Fumet JD, Chevrier S, Derangere V, et al
    Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients.
    Clin Cancer Res. 2018 Aug 28. pii: 1078-0432.CCR-18-1940.
    PubMed     Text format     Abstract available
    
    
    
79. PINE SR
    Rethinking gamma-secretase inhibitors for treatment of non-small cell lung cancer: Is Notch the target?
    Clin Cancer Res. 2018 Aug 13. pii: 1078-0432.CCR-18-1635.
    PubMed     Text format     Abstract available
    
    
    
80. SONG KA, Hosono Y, Turner C, Jacob S, et al
    Increased synthesis of MCL-1 protein underlies initial survival of EGFR mutant lung cancer to EGFR inhibitors and provides a novel drug target.
    Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-0304.
    PubMed     Text format     Abstract available
    
    
    
81. KIM ES, Kelly K, Paz-Ares L, Garrido P, et al
    Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase 1b Study.
    Clin Cancer Res. 2018 Aug 6. pii: 1078-0432.CCR-18-0651.
    PubMed     Text format     Abstract available
    
    
    
82. BAHCALL M, Awad MM, Sholl LM, Wilson FH, et al
    Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer.
    Clin Cancer Res. 2018 Aug 2. pii: 1078-0432.CCR-18-0876.
    PubMed     Text format     Abstract available
    
    
    
83. WANG Y, Li N, Jiang W, Deng W, et al
    Mutant LKB1 confers enhanced radiosensitization in combination with trametinib in KRAS-mutant non-small cell lung cancer.
    Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-1489.
    PubMed     Text format     Abstract available
    
    
    July 2018
84. PONATH P, Menezes DL, Pan C, Chen B, et al
    A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0018.
    PubMed     Text format     Abstract available
    
    
    
85. AKIBA T, Morikawa T, Odaka M, Nakada T, et al
    Vitamin D supplementation and survival of patients with non-small-cell lung cancer: A randomized, double-blind, placebo-controlled trial.
    Clin Cancer Res. 2018 Jul 17. pii: 1078-0432.CCR-18-0483.
    PubMed     Text format     Abstract available
    
    
    
86. ROMANIELLO D, Mazzeo L, Mancini M, Marrocco I, et al
    A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways.
    Clin Cancer Res. 2018 Jul 2. pii: 1078-0432.CCR-18-0450.
    PubMed     Text format     Abstract available
    
    
    June 2018
87. LI S, Liu S, Deng J, Akbay EA, et al
    Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-17-3438.
    PubMed     Text format     Abstract available
    
    
    
88. KO EC, Raben D, Formenti SC
    The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-17-3620.
    PubMed     Text format     Abstract available
    
    
    
89. LAIRD JH, Lok BH, Ma J, Bell A, et al
    Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-18-0401.
    PubMed     Text format     Abstract available
    
    
    
90. LALLO A, Frese KK, Morrow C, Szczepaniak Sloane R, et al
    The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-17-2805.
    PubMed     Text format     Abstract available
    
    
    
91. SAIGI M, Alburquerque-Bejar JJ, McLEER-Florin A, Pereira C, et al
    MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer.
    Clin Cancer Res. 2018 Jun 13. pii: 1078-0432.CCR-18-0267.
    PubMed     Text format     Abstract available
    
    
    May 2018
92. BAUML J, Levy B
    Clonal Hematopoiesis: A new layer in the liquid biopsy story in lung cancer.
    Clin Cancer Res. 2018 May 10. pii: 1078-0432.CCR-18-0969.
    PubMed     Text format     Abstract available
    
    
    
93. HIGGS BW, Morehouse C, Streicher KL, Brohawn P, et al
    Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small-Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3451.
    PubMed     Text format     Abstract available
    
    
    
94. NAZ S, Sowers AL, Choudhuri R, Wissler MF, et al
    Abemaciclib, a Selective CDK4/6 Inhibitor Enhances the Radiosensitivity of Non-Small Cell Lung Cancer in vitro and in vivo.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3575.
    PubMed     Text format     Abstract available
    
    
    April 2018
95. CLARET L, Jin JY, Ferte C, Winter H, et al
    A model of overall survival predicts treatment outcomes with atezolizumab vs chemotherapy in non-small cell lung cancer based on early tumor kinetics.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3662.
    PubMed     Text format     Abstract available
    
    
    
96. MCCOACH CE, Le A, Gowan K, Jones KL, et al
    Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.
    Clin Cancer Res. 2018 Apr 10. pii: 1078-0432.CCR-17-2452.
    PubMed     Text format     Abstract available
    
    
    
97. IOMMELLI F, De Rosa V, Terlizzi C, Monti M, et al
    Inositol trisphosphate receptor type 3-mediated enhancement of EGFR and MET co-targeting efficacy in non-small cell lung cancer detected by 18F-fluorothymidine.
    Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-3657.
    PubMed     Text format     Abstract available
    
    
    
98. FRANK R, Scheffler M, Merkelbach-Bruse S, Ihle MA, et al
    Clinical and pathological characteristics of KEAP1- and NFE2L2- mutated non-small cell lung carcinoma (NSCLC).
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-17-3416.
    PubMed     Text format     Abstract available
    
    
    March 2018
99. MCCOACH CE, Blakely CM, Banks KC, Levy BM, et al
    Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-2588.
    PubMed     Text format     Abstract available
    
    
    
100. HORN L, Infante JR, Reckamp KL, Blumenshein GR, et al
     Ensartinib (X-396) in ALK-positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
     Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-2398.
     PubMed     Text format     Abstract available
     
     
     
101. CASTELLANOS-RIZALDOS E, Grimm DG, Tadigotla V, Hurley J, et al
     Exosome-based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.
     Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-3369.
     PubMed     Text format     Abstract available
     
     
     
102. YANG Z, Yang N, Ou Q, Xiang Y, et al
     Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients.
     Clin Cancer Res. 2018 Mar 5. pii: 1078-0432.CCR-17-2310.
     PubMed     Text format     Abstract available
     
     
     
103. CAPPUZZO F, Landi L
     HER2 deregulation in lung cancer: right time to adopt an orphan?
     Clin Cancer Res. 2018 Mar 1. pii: 1078-0432.CCR-18-0198.
     PubMed     Text format     Abstract available
     
     
     February 2018
104. BILLATOS E, Vick JL, Lenburg ME, Spira AE, et al
     The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection.
     Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-16-3187.
     PubMed     Text format     Abstract available
     
     
     
105. TIAN Y, Wang Z, Liu X, Duan J, et al
     Prediction of chemotherapeutic efficacy in non-small cell lung cancer by serum metabolomic profiling.
     Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2855.
     PubMed     Text format     Abstract available
     
     
     
106. YU J, Wang S, Zhao W, Duan J, et al
     Mechanistic exploration of cancer stem cell marker voltage-dependent calcium channel alpha2delta1 subunit-mediated chemotherapy resistance in small cell lung cancer.
     Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-1932.
     PubMed     Text format     Abstract available
     
     
     
107. MACLEOD AK, Lin, Huang JT, McLaughlin LA, et al
     Identification of novel pathways of osimertinib disposition and potential implications for the outcome of lung cancer therapy.
     Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3555.
     PubMed     Text format     Abstract available
     
     
     January 2018
108. MCCALL NS, Dicker AP, Lu B
     Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer.
     Clin Cancer Res. 2018 Jan 22. pii: 1078-0432.CCR-17-3269.
     PubMed     Text format     Abstract available
     
     
     
109. KITAJIMA S, Barbie DA
     RASA1/NF1 mutant lung cancer: Racing to the clinic?
     Clin Cancer Res. 2018 Jan 17. pii: 1078-0432.CCR-17-3597.
     PubMed     Text format     Abstract available
     
     
     
110. GOLDBERG SB, Narayan A, Kole AJ, Decker RH, et al
     Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
     Clin Cancer Res. 2018 Jan 12. pii: 1078-0432.CCR-17-1341.
     PubMed     Text format     Abstract available
     
     
     
111. THANGAVEL C, Boopathi E, Liu Y, McNair C, et al
     Therapeutic Challenge With a CDK 4/6 Inhibitor Induces an RB-dependent SMAC Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2018 Jan 8. pii: 1078-0432.CCR-17-2074.
     PubMed     Text format     Abstract available
     
     
     
112. LIU S, Li S, Hai J, Wang X, et al
     Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.
     Clin Cancer Res. 2018 Jan 3. pii: 1078-0432.CCR-17-1875.
     PubMed     Text format     Abstract available
     
     
     December 2017
113. YE M, Zhang Y, Gao H, Xu Y, et al
     Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small-Cell Lung Cancer by Activating Src-Mediated Bypass Signaling.
     Clin Cancer Res. 2017 Dec 11. pii: 1078-0432.CCR-17-0396.
     PubMed     Text format     Abstract available
     
     
     
114. AISNER DL, Sholl LM, Berry L, Rossi M, et al
     The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).
     Clin Cancer Res. 2017 Dec 7. pii: 1078-0432.CCR-17-2289.
     PubMed     Text format     Abstract available
     
     
     
115. WANG Q, Zeng F, Sun Y, Qiu Q, et al
     Etk interaction with PFKFB4 modulates chemoresistance of small cell lung cancer by regulating autophagy.
     Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1475.
     PubMed     Text format     Abstract available
     
     
     
116. VILLARROEL-ESPINDOLA F, Yu X, Datar I, Mani N, et al
     Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer.
     Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-2542.
     PubMed     Text format     Abstract available
     
     
     October 2017
117. ARBOUR KC, Jordan EJ, Kim HR, Dienstag J, et al
     Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer.
     Clin Cancer Res. 2017 Oct 31. pii: clincanres.1841.2017.
     PubMed     Text format     Abstract available
     
     
     
118. FABER AC, Song KA, Niederst MJ, Lochmann TL, et al
     Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM.
     Clin Cancer Res. 2017 Oct 19. pii: clincanres.1577.2017.
     PubMed     Text format     Abstract available
     
     
     
119. FAN Y, Zhu X, Xu Y, Lu X, et al
     Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer.
     Clin Cancer Res. 2017 Oct 13. pii: clincanres.1582.2017.
     PubMed     Text format     Abstract available
     
     
     
120. WANG Y, Gudikote J, Giri U, Yan J, et al
     RAD50 expression is associated with poor clinical outcomes after radiotherapy for resected non-small cell lung cancer.
     Clin Cancer Res. 2017 Oct 13. pii: clincanres.1455.2017.
     PubMed     Text format     Abstract available
     
     
     
121. LOHAVANICHBUTR P, Sakoda LC, Amos CI, Arnold SM, et al
     Common TDP1 polymorphisms in relation to survival among small cell lung cancer patients: a multicenter study from the International Lung Cancer Consortium.
     Clin Cancer Res. 2017 Oct 3. pii: clincanres.1401.2017.
     PubMed     Text format     Abstract available
     
     
     September 2017
122. HU X, Liu T, Wu X, Chen T, et al
     Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing Wnt/beta-catenin signaling.
     Clin Cancer Res. 2017 Sep 28. pii: clincanres.1169.2017.
     PubMed     Text format     Abstract available
     
     
     
123. YI JS, Ready N, Healy P, Dumbauld C, et al
     Immune Activation in Early Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
     Clin Cancer Res. 2017 Sep 26. pii: clincanres.2005.2017.
     PubMed     Text format     Abstract available
     
     
     
124. FENG Y, Wang X, Bajaj G, Agrawal S, et al
     Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2017;23:5394-5405.
     PubMed     Text format     Abstract available
     
     
     
125. GU L, Deng JZ, Roy S, Hammond PT, et al
     A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-small Cell Lung Cancer.
     Clin Cancer Res. 2017 Sep 14. pii: clincanres.2186.2016.
     PubMed     Text format     Abstract available
     
     
     August 2017
126. OOKI A, Maleki Z, Tsay JJ, Goparaju CM, et al
     A panel of novel detection and prognostic methylated DNA markers in primary non-small cell lung cancer and serum DNA.
     Clin Cancer Res. 2017 Aug 29. pii: clincanres.1222.2017.
     PubMed     Text format     Abstract available
     
     
     
127. 
     Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
     Clin Cancer Res. 2017;23:4523.
     PubMed     Text format    
     
     
     
128. ENGSTROM L, Aranda R, Lee M, Tovar EA, et al
     Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
     Clin Cancer Res. 2017 Aug 1. pii: clincanres.1192.2017.
     PubMed     Text format     Abstract available
     
     
     July 2017
129. SEN T, Tong P, Diao L, Li L, et al
     Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small cell lung cancer.
     Clin Cancer Res. 2017 Jul 11. pii: clincanres.1284.2017.
     PubMed     Text format     Abstract available
     
     
     
130. GRAY JE, Heist RS, Starodub AN, Camidge DR, et al
     Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
     Clin Cancer Res. 2017 Jul 5. pii: clincanres.0933.2017.
     PubMed     Text format     Abstract available
     
     
     
131. NISHINO M, Dahlberg SE, Adeni AE, Lydon C, et al
     Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome.
     Clin Cancer Res. 2017 Jul 5. pii: clincanres.1434.2017.
     PubMed     Text format     Abstract available
     
     
     
132. ADAMS DL, Adams DK, He J, Kalhor N, et al
     Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy.
     Clin Cancer Res. 2017 Jul 5. pii: clincanres.0802.2017.
     PubMed     Text format     Abstract available
     
     
     June 2017
133. MALCHERS F, Ercanoglu MS, Schutte D, Castiglione R, et al
     Mechanisms of primary drug resistance in FGFR1 amplified lung cancer.
     Clin Cancer Res. 2017 Jun 19. pii: clincanres.0478.2017.
     PubMed     Text format     Abstract available
     
     
     
134. WEINSTOCK C, Khozin S, Suzman D, Zhang L, et al
     U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2017 Jun 13. pii: clincanres.0540.2017.
     PubMed     Text format     Abstract available
     
     
     
135. JIN X, Chen Y, Chen H, Fei S, et al
     Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early stage non-small-cell lung cancer using next-generation sequencing.
     Clin Cancer Res. 2017 Jun 12. pii: clincanres.0577.2017.
     PubMed     Text format     Abstract available
     
     
     May 2017
136. CASCONE T, Xu L, Lin HY, Liu W, et al
     The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer.
     Clin Cancer Res. 2017 May 30. pii: clincanres.3216.2016.
     PubMed     Text format     Abstract available
     
     
     
137. JEONG J, Oh JH, Sonke JJ, Belderbos JSA, et al
     Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.
     Clin Cancer Res. 2017 May 24. pii: clincanres.3277.2017.
     PubMed     Text format     Abstract available
     
     
     
138. LEE JMM, Lee MH, Garon E, Goldman JW, et al
     Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T cell infiltration.
     Clin Cancer Res. 2017 May 3. pii: clincanres.2821.2016.
     PubMed     Text format     Abstract available
     
     
     April 2017
139. COOPER WA, Russell PA, Cherian M, Duhig EE, et al
     Intra- and Inter-Observer Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC).
     Clin Cancer Res. 2017 Apr 18. pii: clincanres.0151.2017.
     PubMed     Text format     Abstract available
     
     
     
140. LI AN, Yang J, Zhang XC, Zhang Z, et al
     Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer.
     Clin Cancer Res. 2017 Apr 10. pii: clincanres.3273.2016.
     PubMed     Text format     Abstract available
     
     
     March 2017
141. TANG C, Welsh JW, de Groot P, Massarelli E, et al
     Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
     Clin Cancer Res. 2017;23:1388-1396.
     PubMed     Text format     Abstract available
     
     
     
142. BRANT R, Sharpe A, Liptrot T, Dry JR, et al
     Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.
     Clin Cancer Res. 2017;23:1471-1480.
     PubMed     Text format     Abstract available
     
     
     
143. LIU Y, Balagurunathan Y, Atwater T, Antic S, et al
     Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules.
     Clin Cancer Res. 2017;23:1442-1449.
     PubMed     Text format     Abstract available
     
     
     
144. SCARBOROUGH HA, Helfrich BA, Casas-Selves M, Schuller AG, et al
     AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
     Clin Cancer Res. 2017;23:1531-1541.
     PubMed     Text format     Abstract available
     
     
     
145. KURZROCK R, Stewart DJ
     Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
     Clin Cancer Res. 2017;23:1137-1148.
     PubMed     Text format     Abstract available
     
     
     January 2017
146. DAMA E, Melocchi V, Dezi F, Pirroni S, et al
     An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
     Clin Cancer Res. 2017;23:62-72.
     PubMed     Text format     Abstract available
     
     
     July 2016
147. BALLARD P, Yates JW, Yang Z, Kim DW, et al
     Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
     Clin Cancer Res. 2016 Jul 19. pii: clincanres.0399.2015.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: